ABSTRACT
Objective:To explore the efficacy of apatinib combined with S-1 capsule in the treatment of patients with advanced recurrent and metastatic esophageal cancer.Methods:A total of 140 patients with advanced esophageal cancer were selected as test subjects from January 2017 to January 2019 in Shandong Tai′an Cancer Prophylaction-Therapeutic Hospital. These patients were randomly divided into observation group (72 cases) and control group (68 cases) using random number table method. The patients in the observation group were treated with oral apatinib combined with S-1 chemotherapy, and the patients in the control group was only given S-1 chemotherapy. The short-term and long-term efficacy and adverse reactions of the two groups were observed.Results:The objective remission rates of the observation group was 38.9% (28/72), higher than that in the control group (22.1%, 15/68), with a statistically significant difference ( χ2=4.655, P=0.031). The disease control rate of the observation group was 88.9% (64/72), higher than that in the control group (61.8%, 42/68), and there was a significant difference between the two groups ( χ2=13.993, P<0.001). The median progression-free survival of the observation group and the control group was 5.9 months and 2.7 months respectively, the median overall survival was 14.8 months and 7.9 months respectively, and there were significant differences between the two groups ( χ2=5.477, P=0.026; χ2=6.083, P=0.014). The adverse reactions of the two groups were mild, grade 1-2, mainly including fatigue, leukopenia, hand-foot syndrome, hypertension and proteinuria, with incidences of 59.7% (43/72), 50.0% (36/72), 8.3% (6/72), 12.5% (9/72), 9.7% (7/72) in the observation group, and 51.5% (35/68), 57.4% (39/68), 17.6% (12/68), 4.4% (3/68), 4.4% (3/68) in the control group, there were no significant differences between the two groups ( χ2=0.965, P=0.326; χ2=0.760, P=0.383; χ2=2.708, P=0.100; χ2=2.919, P=0.088; χ2=0.794, P=0.373). Conclusion:Apatinib combined with S-1 is effective, safe and tolerable in the treatment of recurrent and metastatic esophageal cancer.
ABSTRACT
Objective To evaluate the therapeutic efficiency and side effect of concurrent radiotherapy and weekly chemotherapy with low-dose eisplatin(DDP) and 5-fluorouracil(5-FU) for advanced cervical canc-er. Methods 73 patients with advanced cervical cancer were randomized into two groups: 37 cases in the chemo-radiotherapy group received radiotherapy combined with DDP 40 mg and 5-FU 500 mg weekly for 6-7 weeks. 36 cases in the only radiotherapy group received radiotherapy alone. Radiotherapy was given with conven-tional fraction,the total tumor dose was 50 Gy. Results The rate of overall response and three-year survival and local recurrenc and distant metastasis for the chemo-radiotherapy group and the only radiotherapy group were 97.30%, 89. 19%, 8. 11% and 10. 81%, and those for the only radiotherapy group were 77.78%,66. 67% ,30.56% and 33.33%. The difference of the four groups was statistically significant ( P <0. 05). The rate of bone marrow inhibition and reaction of digestive tract in chemo-radiotherapy group were higher than those in simple radiotherapy group, but most reactions were grade 1 and grade 2, without statistically significant dife-renee between two groups. Conclusion Concurrent radiotherapy and weekly chemotherapy with low-dose cis-platin and 5-fluorouracil for advanced cervical cancer can significantly improve local control rate and survival rate, and have slight side effects.